Glembatumumab vedotin is an new method in malignancy therapy. This ADC selectively binds to a molecule expressed on several cancer cells, transporting an effective cytotoxic agent. Preliminary patient studies suggest https://www.targetmol.com/compound/glembatumumab_vedotin